...
首页> 外文期刊>Scientific reports. >Time course of focused ultrasound effects on β-amyloid plaque pathology in the TgCRND8 mouse model of Alzheimer’s disease
【24h】

Time course of focused ultrasound effects on β-amyloid plaque pathology in the TgCRND8 mouse model of Alzheimer’s disease

机译:聚焦超声效应对阿尔茨海默病TGCRND8小鼠模型中β-淀粉样噬斑病理的

获取原文
           

摘要

Previous studies have demonstrated that temporarily increasing the permeability of the blood-brain barrier using focused ultrasound can reduce β-amyloid plaque load and improve cognitive function in animal models of Alzheimer’s disease. However, the underlying mechanism and duration for which the effects of one treatment persists for are unknown. Here, we used in vivo two-photon fluorescence microscopy to track changes in β-amyloid plaque sizes in the TgCRND8 mouse model of Alzheimer’s disease after one focused ultrasound treatment. We found that one treatment reduced plaques to 62?±?16% ( p ≤?0.001) of their original volume two days post-sonication; this decrease in size persisted for two weeks. We then sought to evaluate the effectiveness of biweekly focused ultrasound treatments using magnetic resonance imaging-guided focused ultrasound treatments. Three to five biweekly treatments resulted in a 27?±?7% ( p ≤?0.01) decrease in plaque number and 40?±?10% ( p ≤?0.01) decrease in plaque surface area compared to untreated littermates. This study demonstrates that one focused ultrasound treatment reduces the size of existing β-amyloid plaques for two weeks, and that repeated biweekly focused ultrasound treatments is an effective method of reducing β-amyloid pathology in moderate-to-late stages of Alzheimer’s disease.
机译:以前的研究表明,使用聚焦超声暂时增加血脑屏障的渗透性可以降低β-淀粉样噬斑块并改善阿尔茨海默病的动物模型中的认知功能。然而,一个治疗效果持续存在的潜在机制和持续时间是未知的。这里,我们用于体内两光子荧光显微镜,以在一个聚焦的超声处理后,在Alzheimer疾病的TGCRND8小鼠模型中跟踪β-淀粉样斑块的变化。我们发现一个治疗将斑块减少到62°?±16%(P≤≤upply)其原始卷后两天后超声处理;这种尺寸减小持续两周。然后,我们试图使用磁共振成像引导的超声处理来评估双周聚焦超声处理的有效性。三到五个双周处理导致27?±7%(p≤≤0.01),斑块数减少,40?±10%(p≤≤0.01)与未处理的凋落物相比斑块表面积减少。该研究表明,一个聚焦超声处理减少了现有β-淀粉样斑块的尺寸两周,并且重复的双周聚焦的超声处理是在阿尔茨海默病的中度至晚期阶段中降低β-淀粉样蛋白病理的有效方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号